by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.
by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.
by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.
by Bruce Sylvester: Anastrozole appears to be as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer, and could offer… read more.
The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.
Gene expression profiling (GEP) is currently the best approach for defining risk in multiple myeloma (MM). Mutation detection may be used for improving risk stratification and providing additional… read more.
Specialists in the MM field are in the enviable position of having lots of different treatment options available – the challenge is how to integrate these into the… read more.
Multiple myeloma is unique amongst cancers in that the diagnosis is made by the clinician, not the pathologist. The pathologist merely states that the patient has a clonal… read more.
IMW President, Professor Antonio Palumbo (Torino, Italy) gives his highlights, along with Dr Noopar Raje (Boston, USA) , Professor Faith Davies, (Little Rock, USA) and Professor Paul Richardson (Boston, USA).
Vijayveer Bonthapally et al, Cambridge, MA, USA / by Maria Dalby. AETHERA is a randomised, placebo-controlled phase III study to evaluate whether consolidation treatment with brentuximab vedotin can… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
